Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Lux Biosciences, Inc.
Age
13–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
A documented history of non-infectious intermediate, anterior and intermediate, posterior or panuveitis.
Minimum prescribed therapy upon enrollment is one or more of the following:
* systemic prednisone or equivalent averaging ≥ 10 mg/day
* at least 2 periocular/intravitreal corticosteroid administrations for control of inflammatory disease within the previous 8 months (but not within 6 weeks of randomization).
* at least one, but not more than 2 immunosuppressive drugs from among the following compounds: cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, methotrexate
Subjects with clinically quiescent uveitis in both eyes at enrollment and who have been on a stable treatment regimen for a minimum of 6 weeks
Best-corrected distance visual acuity in the worst involved eye of 20/400 or better (ETDRS logMAR \<1.34)
Subjects not planning to undergo elective ocular surgery during the study
You may not be if
Evidence of active, uncontrolled non-infectious uveitis
Periocular administration of corticosteroids within the previous 6 weeks.
Uveitis of infectious etiology
Uncontrolled glaucoma
Clinically suspected or confirmed central nervous system or ocular lymphoma
History or diagnosis of Behçet's disease
Primary diagnosis of anterior uveitis
Clareo Health | A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis
